Reteplase ( rPA ) for injection

It is suitable for the thrombolysis in myocardial infarction induced by coronary artery infarction in adults, and it can improve the ventricular functions after myocardial infarction. This drug should be used as early as possible within 12 hours after the symptoms are detected. "Highlights: 1, the Third generation anticoagulant, antiplatelet,fibrinolytic agent while the originator Actilyse® by Boehringer Ingelheim is the second generation of thrombolytic drug. 2, Less dosage: Reteplase (18 mg+18mg, >2 Mins) VS Actilyse® (100mg, 90Mins) 3, higher reunobstructed ratio, faster thrombolysis speed and longer half-life period than Actilyse® 4, Minor adverse reactions 5, Time to market: 2007 6, Exported countries: Pakistain (already registered); 7, Sales turnover of our product in China: RMB 60 million in 2012 Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part."